Glucotrack Inc. will host a virtual webinar on May 29 to showcase its innovative Continuous Blood Glucose Monitor (CBGM) technology, offering insights into a potential breakthrough in diabetes care management. The webinar aims to highlight the company's unique approach to addressing the challenges faced by diabetes patients in monitoring their blood glucose levels.
Current diabetes management tools typically require patients to repeatedly prick their fingers to test blood sugar, a process that can be both invasive and cumbersome. Glucotrack's CBGM technology presents a significantly different solution, providing real-time glucose monitoring through an implantable device that can last two to three years, compared to existing continuous glucose monitors that require frequent replacement.
The key differentiator of Glucotrack's technology is its ability to measure glucose directly in the bloodstream, eliminating the lag time associated with traditional subcutaneous sensors that measure glucose in interstitial fluid. A recent preclinical study demonstrated the device's accuracy, achieving a Mean Absolute Relative Difference (MARD) of 4.7% at 90 days, which is considered highly precise in the medical technology field.
The webinar comes at a critical time, as diabetes is projected to impact 643 million people globally by 2030, with estimates rising to 783 million by 2045. By offering a more sophisticated and less intrusive monitoring solution, Glucotrack's technology could significantly improve patient experience and diabetes management.
During the one-hour virtual event, Glucotrack executives will provide detailed insights into their CBGM technology, share updates on ongoing clinical trials, and discuss the future of diabetes management. The session will conclude with a live Q&A, allowing attendees to engage directly with the company's experts.
